Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25‐dihydroxyvitamin D

@article{Slovik1986RestorationOS,
  title={Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25‐dihydroxyvitamin D},
  author={D. Slovik and D. Rosenthal and S. Doppelt and J. Potts and M. Daly and J. Campbell and R. Neer},
  journal={Journal of Bone and Mineral Research},
  year={1986},
  volume={1}
}
Daily subcutaneous injection of a synthetic human parathyroid hormone fragment, combined with daily ingestion of 1,25(OH)2 vitamin D, significantly increased trabecular bone density in the spine (p < .01), and improved intestinal calcium and phosphorus absorption and total body retention of dietary calcium and phosphorus in middle‐aged men with idiopathic osteoporosis. The increases in spinal bone mineral were marked and progressive during a year of treatment. These results indicate that… Expand
Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol
An ideal treatment for osteoporosis would increase bone strength by increasing the amount of mineralized lamellar bone, the thickness of cortical bone, and the connectivity of trabecutar bone, andExpand
Treatment of osteoporosis with parathyroid peptide (hPTH 1–34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone
TLDR
Treatment of vertebral osteoporosis with human parathyroid peptide 1–34, given as a daily injection with supplementary treatment with hormone replacement therapy (HRT), increases cancellous bone area in the ilium by increasing the size of packets of new bone. Expand
Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride.
TLDR
Treatment of postmenopausal women with human parathyroid peptide selectively increases spinal cancellous bone density by amounts that may prove useful in secondary prevention as the usefulness of sodium fluoride in this context is doubtful. Expand
Parathyroid Hormone for the Treatment of Osteoporosis
  • M. McClung
  • Medicine
  • Obstetrical & gynecological survey
  • 2004
TLDR
This review highlights the effects of parathyroid hormone on bone density and fracture risk in patients with osteoporosis and addresses several of the important issues pertaining to the use of these new agents in daily clinical practice. Expand
Sequential effects of chronic human PTH (1‐84) treatment of estrogen‐deficiency osteopenia in the rat
TLDR
It is demonstrated that both osteoblast and osteoclast function are increased during daily PTH therapy in the rat, and the pattern of response depends on both the dose of PTH and the duration of therapy. Expand
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
TLDR
Alendronate impairs the ability of parathyroid hormone to increase the bone mineral density at the lumbar spine and the femoral neck in men. Expand
Growth hormone does not enhance the anabolic effect of human parathyroid hormone (1–34) on bone in aging multiparous and virgin rats
TLDR
PTH alone stimulated bone formation and increased bone mass in three of four experiments and consistently increased serum 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) and mineral retention, more than either hormone alone. Expand
Human parathyroid peptide treatment of vertebral osteoporosis
TLDR
It is concluded that in combination with oestrogens, hPTH peptides given daily injections hold great promise for the treatment of patients with osteoporosis who have already lost substantial amounts of spinal cancellous bone. Expand
Parathyroid Hormone in the Treatment of Osteoporosis
TLDR
Because of its bone anabolic action, PTH is expected to be effective for osteoporosis in those of advanced age with suppressed bone remodelling, which might not respond favourably to antiresorptive agents. Expand
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.
TLDR
PTH is a potent stimulator of skeletal dynamics inMen with idiopathic, low turnover osteoporosis; is associated with substantial increases in lumbar spine and hip bone density; and may prove to be an efficacious anabolic agent in men with this disorder. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.
TLDR
Those patients who had the largest increases in 47Ca-kinetic and histomorphometric indices of new bone formation showed the greatest increases in trabecular bone volume, suggesting that treatment with human parathyroid hormone fragment caused a dissociation between formation and resorption rates that was confined to trabECular bone. Expand
Short-term effects of synthetic human parathyroid hormone-(1--34) administration on bone mineral metabolism in osteoporotic patients.
TLDR
It is indicated that low doses of parathyroid hormone may promote bone formation, whereas higher doses clearly have an adverse effect on the skeleton. Expand
Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds.
TLDR
The adult greyhound was found to be similar to adult man with respect to kinetic and histomorphometric indices of calcium metabolism and it is possible that the increased osteoblastic activity induced by the daily injection regime in trabecular bone is dependent on the noncontinuous nature of the PTH stimulus. Expand
Increase of whole-body calcium and skeletal mass in normal and osteoporotic adult rats treated with parathyroid hormone.
TLDR
The results show that PTH can enhance skeletal mass in both normal and osteoporotic rats, and in osteoporeotic animals the restoration of whole-body calcium and ash weight of individual bones is not accompanied by a return of the morphological structure of the tibia to normal. Expand
Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone.
TLDR
Results indicate that trabecular bone mass did not increase at the expense of cortical bone, and the bone response with changes in serum calcium or phosphate did not differ significantly from control serum calcium, serum phosphate, or serum phosphate. Expand
Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration.
TLDR
The results suggest that the resorptive effects of bPTH-(1-84) can be separated from the effects of the hormone on the apposition rate, and also found an increase in both formation and resorption surfaces and a net decrease in the trabecular bone volume in this group. Expand
Prevention of early postmenopausal bone loss: controlled 2‐year study in 315 normal females
TLDR
This study randomized 315 healthy volunteers in their early natural menopause to seven treatment and three placebo groups, with the aim of preventing postmenopausal bone loss. Expand
1,25-Dihydroxyvitamin D3: short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis.
TLDR
The effects of therapy with a small dose of 1,25-dihydroxyvitamin D3 in 12 previously untreated patients with postmenopausal osteoporosis and eight patients studied before and after 6-8 months of placebo treatment had no significant change in any variable. Expand
Action of 1alpha-hydroxy vitamin D3 on calcium absorption and bone resorption in man.
TLDR
Synthetic 1α-H.C.C (1α-hydroxy-vitamin D 3) is very potent in man and will be useful in treatment of patients with calcium malabsorption, but the dose needs to be less than 25 μg. Expand
Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients.
TLDR
It is possible that a deficiency in 1,25-(OH)2-D secretory reserve will explain the inability of elderly osteoporotic patients to adapt to the low-calcium diets common in this age group and this phenomenon may play a part in the pathogenesis of age-related osteoporeosis. Expand
...
1
2
3
...